Medical treatment of thyroid carcinoma

  • William H. Beierwaltes
Part of the Cancer Treatment and Research book series (CTAR, volume 20)


Since this chapter is entitled the Medical treatment of thyroid carcinoma most of the emphasis will be on the treatment of papillary and follicular carcinoma of the thyroid with radioactive iodine, Na131I. Other thyroid malignancies will be discussed primarily as they relate to the above topic. Similarly, the diagnosis and classification of thyroid malignancies will be discussed only as they relate to medical treatment.


Thyroid Cancer Thyroid Carcinoma Papillary Thyroid Carcinoma Total Thyroidectomy Papillary Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Third National Cancer Survey, N.C.I. Monograph 41, 1975.Google Scholar
  2. 2.
    Incidence, five leading cancer sites in young adult females (15–34) Ca-A. Cancer Journal for Clinicians 32: 39, Jan/Feb, 1982. (From Biometry Branch, National Cancer Institute)Google Scholar
  3. 3.
    Williams ED, Doniach MD, Bjorenson O, et al.: Thyroid cancer in an iodine rich area. Cancer 39: 215, 1977.PubMedCrossRefGoogle Scholar
  4. 4.
    Thompson NW, Nishiyama RN, Harkness JK: Thyroid carcinoma: Current controversies. Curr Prob Surg 25: 1–17, 1978.Google Scholar
  5. 5.
    Beierwaltes WH, Nishiyama RN, Thompson NW, et al.: Survival time and ‘cure’ in papillary and follicular thyroid carcinoma with distant metastases: Statistics following University of Michigan therapy. J Nucl Med 23: 561, 1982.PubMedGoogle Scholar
  6. 6.
    Winship T and Rosvoll RW: Childhood thyroid carcinoma. Cancer 14: 734, 1961.PubMedCrossRefGoogle Scholar
  7. 7.
    Rawson RW, Leeper RD: Chapter 27, Treatment of thyroid cancer with radioactive iodine. In: Nuclear Medicine, 2nd ed., Blahd WH. Blakiston: McGraw Hill Book Co., 1965, p 745.Google Scholar
  8. 8.
    Perzik SL: Total thyroidectomy in Graves’ disease in children. J Pediatr Surg 11: 191, 1976.PubMedCrossRefGoogle Scholar
  9. 9.
    Thompson NW, Dunn EL, Freitas JE, et al.: Surgical treatment of thyrotoxicosis in children and adolescents. J Pediatr Surg 12: 1009, 1977.PubMedCrossRefGoogle Scholar
  10. 10.
    Leeper RD: The effect of 131I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol Metab 36: 1143, 1973.PubMedCrossRefGoogle Scholar
  11. 11.
    Leeper RD: Controversies in the treatment of thyroid cancer: The New York Memorial Hospital approach. Thyroid Today,, July/August, 1982.Google Scholar
  12. 12.
    Beierwaltes WH, Johnson PC: Thyroid carcinoma treated with radioactive iodine. An eight-year experience. J Mich State Med Soc 55: 410, 1956.PubMedGoogle Scholar
  13. 13.
    Beierwaltes WH: The treatment of thyroid carcinoma with radioactive iodine. Sem Nucl Med 8: 79–94, 1978.CrossRefGoogle Scholar
  14. 14.
    Sawyer VL, Block MD, Bowman HE: Results of surgical management of carcinoma of the thyroid. J Mich State Med Soc 56: 468, 1957.PubMedGoogle Scholar
  15. 15.
    Block MD: Well differentiated carcinomas of the thyroid. In: Current Problems in Cancer. Vol 3, 1979, Year Book Med Publ Inc, 1979, pp 1–60.Google Scholar
  16. 16.
    Mazzaferri EL, Young RL, Oertel JE, et al.: Papillary thyroid carcinoma: The impact of therapy in 576 patients. Medicine 56: 171, 1977.PubMedCrossRefGoogle Scholar
  17. 17.
    Mazzaferri EL: Papillary thyroid carcinoma: A10 year follow-up report of the impact of therapy in 576 patients. Am J Med 70: 511, 1981.PubMedCrossRefGoogle Scholar
  18. 18.
    Maheshuari YK, Hill CS, Jr., Haynie TP, et al.: 131I therapy in differentiated thyroid carcinoma: M.D. Anderson Hospital experience. Cancer 47: 664, 1981.CrossRefGoogle Scholar
  19. 19.
    Bestagno MF, Pagliaini R, Mavra G, Terzi A: The Use of radioiodine in the management of the differentiated thyroid cancer. Radioanalytical Chemistry 65: 239, 1981.CrossRefGoogle Scholar
  20. 20.
    McCowen KD, Adler RA, Ehaed N, et al.: Low dose radioiodine thyroid ablation in post surgical patients with thyroid cancer. Am J Med 61: 52, 1976.PubMedCrossRefGoogle Scholar
  21. 21.
    Kuni CC, Klingensmith WC: Failure of low doses of 131I to ablate residual thyroid tissue following surgery for thyroid cancer. Radiol 137: 773, 1980.Google Scholar
  22. 22.
    Siddigarri AR, Edmanson J, Wellman HH, et al.: Feasibility of low doses of 131I for thyroid ablation in post surgical patients with thyroid carcinoma. Clin Nucl Med 6: 158, 1981.CrossRefGoogle Scholar
  23. 23.
    Chabner BA: Second neoplasmA complication of cancer chemotherapy. N Engl J Med 297: 213, 1977.PubMedCrossRefGoogle Scholar
  24. 24.
    Beierwaltes WH, Copp JE: Relationship of millicure dose of 131I for ablation of thyroid remnants to results in patients with well-differentiated thyroid carcinoma. (In preparation).Google Scholar
  25. 25.
    Freedburg AS, Kurland GA, Blumgart HL: The pathologic effects of 1–131 on the normal thyroid gland of man. J Clin Endocr 12: 1315, 1952.CrossRefGoogle Scholar
  26. 26.
    Varma VM, Beierwaltes WH, Nofal MH, Nishiyama RH and Copp J: Treatment of thyroid cancer: Death rates after surgery, and after surgery followed by 131I. JAMA 214: 1437–1442, 1970.PubMedCrossRefGoogle Scholar
  27. 27.
    Benua RS, Cicale NR, Sonenberg M, et al.: The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgen 87: 171, 1962.PubMedGoogle Scholar
  28. 28.
    Phillips AF: The gamma ray dose in carcinoma of the thyroid treated by radioiodine. Acta Radiol 41: 533, 1954.PubMedCrossRefGoogle Scholar
  29. 29.
    Harness JK, Thompson NW, Sisson JC, et al.: Differentiated thyroid carcinomas: Treatment of distant metastases. Arch of Surg 108: 410, 1974.Google Scholar
  30. 30.
    Beierwaltes WH: New horizons for therapeutic Nuclear Medicine in 1981. J Nucl Med 22: 549, 1981.PubMedGoogle Scholar
  31. 31.
    Sisson JC, Beierwaltes WH: The effect of thyroidectomy with and without thyroxine replacement on transplantable thyroid tumors in rats. Endocrinology 74: 925–929, 1964.PubMedCrossRefGoogle Scholar
  32. 32.
    Kumar MS, Chiang T, Deodhar SD: Enhancing effect of thyroxine on tumor growth and metastases in syngeneic mouse tumor systems. Cancer Res 39: 3515, 1979.PubMedGoogle Scholar
  33. 33.
    Vonderhaar BK, Greco AE: Effect of thyroid status on development of spontaneous mammary tumors in primiparous C3H mice. Cancer Res 42: 4553, 1982.PubMedGoogle Scholar
  34. 34.
    Krishnamurthy GT, Blobd WH: Human reactions to bovine TSH. J Nucl Med 18: 629, 1977. (abstract).Google Scholar
  35. 35.
    Hays MT, Solomon DH, Beall GN: Suppression of human thyroid function by antibodies to bovine thyrotropin. J Clin Endocrinol Metab 27: 1540, 1967.PubMedCrossRefGoogle Scholar
  36. 36.
    Hershman JM, Edwards CL: Serum thyrotropin (TSH) levels after thyroid ablation compared with TSH levels after exogenous bovine TSH: Implications for 131I treatment of thyroid carcinoma. J Clin Endocrinol Metab 34: 814, 1972.PubMedCrossRefGoogle Scholar
  37. 37.
    Gershengorn MC, Weintraub BD, Robbins J: Response to oral thyrotropin releasing hormone in athyreotic patients with thyroid cancer. In: Proceedings of 7th International Thyroid Conference, Boston 1975, Robbins J, Braverman LE (eds). In: Excerpta Medica International Congress Series #378, 1975, p 575.Google Scholar
  38. 38.
    Goldman JM, Line BR, Aamodt RL, Robbins J: Influence of triiodothyronine withdrawal time on 131I uptake postthyroidectomy for thyroid cancer. J Clin Endocrinol Metab 50: 734, 1980.PubMedCrossRefGoogle Scholar
  39. 39.
    Singer PA, Nicoloff JF, Stein RB, Joravillo J: Transient TRH deficiency after prolonged thyroid hormone therapy. J Clin Endocrinol Metab 47: 512, 1978.PubMedCrossRefGoogle Scholar
  40. 40.
    Krugman LG, Hershman JM, Chapra IV, et al.: Patterns of recovery of the hypothalmic-pituitary thyroid axis in patients taken off chronic thyroid therapy. J Clin Endocrinol Metab 41: 70, 1975.PubMedCrossRefGoogle Scholar
  41. 41.
    Fukuchi M, Tachibana K, Kuuata K, Nishikawa A, et al.: Thallium-201 imaging in thyroid carcinoma appearance of a lymph node metastasis. J Nucl Med 19: 195–196, 1978.PubMedGoogle Scholar
  42. 42.
    Haroda T, Ito Y, Shimaoka K, Tanigachi T, Watsudo A, Senoo T: Clinical evaluation of 201 Thallium Chloride scan for thyroid nodule. Eur J Nucl Med 5: 125–130, 1980.CrossRefGoogle Scholar
  43. 43.
    Pacini F, Pinchera A, Giani C, Grasso L, Doveri F, Baschieri: Serum thyroglobulin in thyroid carcinoma and other thyroid disorders. J Endocrinol Invest 3: 283, 1980.Google Scholar
  44. 44.
    Schneider AB, Line BR, Goldman JM, Robbins J: Sequential serum thyroglobulin determinations, 131I scans, and 131I uptakes after triiodothyronine withdrawal in patients with thyroid cancer. J Clin Endocrinol Metab 53: 1199, 1981.PubMedCrossRefGoogle Scholar
  45. 45.
    Echenique RL, Kasi L, Haynie TP, Glenn HJ, Samaan NA, Hill CS: Critical evaluation of serum thyroglobulin levels and 1–131 scans in post-therapy patients with differentiated thyroid carcinoma: Concise communication. J Nucl Med 23: 235, 1982.PubMedGoogle Scholar
  46. 46.
    Rawson RW, Rail JE, Peacock W: Limitations and indications in treatment of cancer of thyroid with radioactive iodine. J Clin Endocrinol 11:1128, 1951.CrossRefGoogle Scholar
  47. 47.
    Henk JM, Hirtsman S, Own CM: Whole body scanning and 131I therapy in the management of thyroid carcinoma. Br J Radiol 45: 369, 1972.PubMedCrossRefGoogle Scholar
  48. 48.
    Cady B: Risk factor analysis in differrentiated thyroid cancer. Ann Surg 18: 541, 1976.CrossRefGoogle Scholar
  49. 49.
    Carr EA, Jr., Dingledine WS, Beierwaltes WH: Premature resort to X-ray therapy. A common error in treatment of carcinoma of the thyroid gland. Lancet 78: 478–483, 1958.Google Scholar
  50. 50.
    Haynie TP, Beierwaltes WH: Hematologic changes observed following 1–131 therapy for thyroid carcinoma. J Nucl Med 4: 85–91, 1963.PubMedGoogle Scholar
  51. 51.
    Halron KE: The non-surgical treatment of thyroid cancer. Br J Surg 62: 769, 1975.CrossRefGoogle Scholar
  52. 52.
    Pochin EE: The occurrence of leukemia following radioiodine therapy. In: Advances in Thyroid Research, Pitt-Dinen. New York: Pergammon Press, p 392.Google Scholar
  53. 53.
    Brinckner H, Hanren HR, Anderson AP: Induction of leukemia by 131I treatment of thyroid carcinoma. Br J Cancer 28: 232, 1973.CrossRefGoogle Scholar
  54. 54.
    Rubin P, Landman S, Mayer E: Bone marrow regeneration and extension after extended field irradiation in Hodgkin’s disease. Cancer 32: 699, 1973.PubMedCrossRefGoogle Scholar
  55. 55.
    Knorpe WH, Royudu LMS, Cartello M: Bone marrow scanning with 52 Iron (52Fe) regeneration and extension after ablative doses or radiotherapy. Cancer 37: 1432, 1976.CrossRefGoogle Scholar
  56. 56.
    Hellman DE, Kartchner M, VanAntwerp JD, Salmon SE, Patton DD, O’Mara R: Radioiodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 48: 451, 1979.PubMedCrossRefGoogle Scholar
  57. 57.
    Deftos LJ, Stein MF: Radioiodine as an adjunct to the surgical treatment of medullary thyroid carcinoma: J Clin Endocrinol Metab 50: 967, 1980.PubMedCrossRefGoogle Scholar
  58. 58.
    Porthasarathy KL, Shimaoks K, Bokski SP, et al.: Radiotracer uptake in medullary carcinoma of the thyroid. Clin Nucl Med 5: 45, 1980.CrossRefGoogle Scholar
  59. 59.
    Nusynowitz ML, Pollard E, Benedetto AR, Lecklitner ML, Ware RW: Treatment of medullary carcinoma of the thyroid with 131I. J Nucl Med 23: 143, 1982.PubMedGoogle Scholar
  60. 60.
    Thereston V, Williams ED: The effect of radiation on thyroid C-cells. Acta Endocrinol 99: 72, 1982.Google Scholar
  61. 61.
    Rail JE, Alpers JB, LeWallen CG: Radiation pneumonitis and fibrosis: A complication of radioiodine treatment of pulmonary metastases from cancer of the thyroid. J Clin Endocrinol 17: 1263, 1967.Google Scholar
  62. 62.
    Sarker SD, Beierwaltes WH, Gill SP, et al.: Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med 17: 460–464, 1976.Google Scholar
  63. 63.
    Thomas SR, Maxon NR, Keriakes JG, et al.: Quantitative external counting techniques enabling improved diagnostic and therapeutic decisions in patients with well-differentiated thyroid cancer. Radiology 122: 731, 1977.PubMedGoogle Scholar
  64. 64.
    Koral KF, Adler RS, Carey JE, Kline RC, Beierwaltes WH: Two-orthogonal-view method for quantification of rad dose to neck lesions in thyroid-cancer-therapy patients. Medical Physics 9(4): 497–505, 1982.PubMedCrossRefGoogle Scholar
  65. 65.
    Evans RC: Radium poisoning: II. The quantitative determination of the radium contect and radium elimination rate in living persons. Am J Roetgenol 32: 368, 1937.Google Scholar
  66. 66.
    Scott JS, Halran KE, Shimmins V, et al.: Measurement of dose to thyroid carcinoma metastases from radioiodine therapy. Br J Radiol 43: 256, 1970.PubMedCrossRefGoogle Scholar
  67. 67.
    Block MA, Mitter JM, Horn RC, Jr.: Thyroid carcinoma with cervical lymph node metastasis. Effectiveness of total thyroidectomy and node dissection. Am J Surg 122: 458, 1971.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1984

Authors and Affiliations

  • William H. Beierwaltes

There are no affiliations available

Personalised recommendations